Cerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier ResearchBusiness Wire • 09/01/22
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And OthersInvestors Business Daily • 08/29/22
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA NephropathyBusiness Wire • 08/29/22
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of DirectorsBusiness Wire • 08/24/22
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on AmyloidosisBusiness Wire • 08/18/22
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart DrugInvestors Business Daily • 08/05/22
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety QuestionedInvestors Business Daily • 08/04/22
Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's WhyInvestors Business Daily • 08/03/22
Alnylam's stock jumps 57% after sharing positive news for its experimental RNAi therapyMarket Watch • 08/03/22
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with CardiomyopathyBusiness Wire • 08/03/22
Alnylam Ranks #1 on Fast Company's Fourth Annual List of the 100 Best Workplaces for InnovatorsBusiness Wire • 08/02/22
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/28/22
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 07/28/22
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period ActivityBusiness Wire • 07/28/22